Among ALT-positive neuroblastoma patients, 5-year event-free survival ranged from 10 % to 23 %, whereas in the TMM-negative sub-cohort event-free survival rates remained consistently above 41 %, peaking at 81 % across groups. Here, GPT is linked to neuroblastoma.